Reversal of multidrug resistance of tumor cells

Anticancer Research

Volumn 20, Issue 6 B, 2000, Pages 4261-4274

  Szabo D ^a   Keyzer, H ^a   Kaiser, H E ^a   Molnar J ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Human mdr1 gene; Mouse lymphoma; Multidrug resistance reversal; Specificity and stereselectivity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; CYTOTOXIC AGENT; DACTINOMYCIN; DITERPENE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; INTERCALATING AGENT; MITHRAMYCIN; MITOMYCIN C; NEUROLEPTIC AGENT; PACLITAXEL; PEPTIDE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; PUROMYCIN; STEROID HORMONE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CHIRALITY; CHROMOSOME 7; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE LOCATION; GENETIC TRANSFECTION; HEAT SHOCK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID SOLUBILITY; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; PH; POINT MUTATION; PRIORITY JOURNAL; REVIEW; TUMOR CELL; ULTRAVIOLET IRRADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; GLYCOSYLATION; HUMANS; MOLECULAR CONFORMATION; P-GLYCOPROTEIN; PHOSPHORYLATION; TUMOR CELLS, CULTURED;

EID: 0034477126     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phthalimido- and chloroethyl-phenothiazines
2. DNA sequence of the white locus of Drosophila melanogaster
3. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum
4. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum
5. Saccharomyces cerevisiae STE6 gene product: A novel pathway for protein export in eukaryotic cells
6. The yeast STE6 gene encodes a homologue of the mamrnalian multidrug resistance P-glycoprotein
7. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
8. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport
9. The 70-kDa peroxisomal membrane protein is a member of the Mdr (P-glycoprotein)-related ATP-binding protein superfamily
10. Mutations in the 70K peroxisomal membrane protein gene in Zellweger syndrome
11. A molecular model of MHC class-I-restricted antigen processing
12. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barriers sites
13. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
14. Rhodamin efflux patterns predict P-glycoprotein substrates in the national cancer institute drug screen
15. Unknotting the complexities of multidrug resistance: The involvement of DNA topoisomerases in drug action and resistance
16. Decreased nuclear matrix DNA topoisomerase 11 in human leukemia cells resistant to VM-26 and m-AMSA
17. Glutathione S-transferaseś and drug resistance
18. Immunohistochemical study of glutathione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivity
19. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II
20. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene
21. Identification of distinct P-glycoprotein gene sequences in rat
22. Identification of members of the P-glycoprotein multigene family
23. Internal: Duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
24. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins
25. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1
26. Structure and expression of the human MDR (P-glycoprotein) gene family
27. Multidrug resistance: Molecular and clinical aspects
28. Molecular mechanisms of multidrug resistance in cancer chemotherapy
29. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdrl gene abolish its ability to confer multidrug resistance
30. Functional analysis of chimeric proteins constructed by exchanging homologous domains of 2 P-glycoproteins conferring distinct drug resistance profiles
31. Biochemistry of multidrug resistance mediated by the multidrug transporter
32. Biochemical basis for multidrug resistance in cancer
33. Genetic basis of multidrug resistance of tumor cells
34. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts
35. P-glycoprotein mediated multidrug resistance, Drug Resistance in Oncology
36. Structure and function of voltage-sensitive ion channels
37. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells
38. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells
39. What have we learnt thus far from mice with disrupted P-glycoprotein genes?
40. Low external pH and osmotic shock increase the expression of human MDR protein
41. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells
42. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs
43. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53
44. Human immunodeficiency virus-1 induced expression of P-glycoprotein
45. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation
46. Enhanced expression by the brain matrix of P-glycoprotein in brain capillary endothelial cells
47. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
48. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PKI)
49. Human P-glycoprotein transports cortisol, aldosterone, and dexarnethasone, but not progesterone
50. Regulation of the multidrug resistance gene in regenerating rat liver
51. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver
52. Continued expression of Vinca alkaloid resistance by CCFR-CEM cells after treatment with tunicamycin or pronase
53. Glycosylation of P-glycoprotein in a multidrug-resistant KB cell line and in human tissues
54. The biochemistry of P-glycoprotein-mediated multidrug resistance
55. N-glycosylation and deletion mutants ofthe human MDR1 P-glycoprotein
56. Phosphorylation of the multidrug resistance associated glycoprotein
57. A phosphoglycoprotein associated with taxol resistance in J 774.2 cells
58. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorllation and relationship to drug accumulation in multidrug resistant human-KB cells
59. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase-C in multidrug resistant MCF-7 cells
60. Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells
61. Differential modulation of P-glycoprotein trasport by protein kinase inhibition
62. Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine
63. Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein
64. Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells
65. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C
66. Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein
67. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine, and phorbol esters
68. Effects of phosphorylation of P-glycoprotein on multidrug resistance
69. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells
70. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers
71. Photoaffinity labeling of the multidrug resistance-related P-glycoprotein with photoactive analogs of verapamil
72. Photoaffinity probes for the alpha 1-adrenergic receptor and the calcium channeI bind to a common domain in P-glycoprotein
73. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185-Val-185 substitution in P-glycoprotein
74. Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance
75. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein
76. Interaction of forskolin with the P-glycoprotein multidrug transporter
77. Characterization of the azidopine and vinblastine binding site of P-glycoprotein
78. Cytoplasmic orientation and two-domain structure of the multidrug transporter, P-glycoprotein, demonstrated with sequence-specific antibodies
79. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12
80. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling
81. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells
82. Mechanisms of multidrug resistance and implications for therapy
83. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation
84. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines
85. Photoaffinity labeling of P-glycoprotein in multidrug resistant cells with photoactive analogs of colchicine
86. Expression of a multidrug resistance gene in human cancers
87. Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance
88. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles
89. Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: Further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein
90. Partial purification and reconstitution of the human multidrug-resistance pump: Characterization of the drug-stimulatable ATP hydrolysis
91. Exploring multidrug resistance using rhodamine 123
92. Clinical trials of agents that reverse multidrug resistance
93. Stereoselective separations of chiral anticancer drugs and their application to pharmacodynamic and pharmacokinetic studies
94. Stereoisomers in clinical oncology: Why it is important to know what the right and left hands are doing
95. Drug resitance and p-glycoprotein expression, DNA topoisomerase II activity and glutatione content in malignant mesothelioma cell lines establised after in vivo chemotherapy
96. D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro
97. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein
98. Modulation of drug cytotoxicity by stereoisomeric series of C-20 vinblastine congmers that lack antimicrotubule activity
99. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs
100. The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse Iymphoma cells
101. 3H-cis-Z-flupenthixol binding and on adenylate cyclase activity in vitro
102. Inhibition of bacterial plasmid replication by stereoselective binding by tricyclic psychopharmacons
103. Differential stereoselectivity of metotrimiprasine enantiomers for selected central nervous system receptor types
104. Cis-trans isomerism
105. Overexpression of sigma receptors in non-neural human tumors
106. Cytotoxic effects of sigma ligands: Sigma receptor-mediated alterations in cellular morphology and viability
107. A sigma-like binding site rat pheochromocytoma PC12 cells
108. Structural determinants of sigma receptor affinity
109. Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase
110. 1251 -L-750
111. Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds
112. Effect of new thioacridine derivatives on p-gp function and on mdrl gene expression
113. Verapamil stereoisomers during racemic verapamil administration: Effects of aging and comparisons to administration of individual stereoisomers
114. Successfu'l control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer
115. Delirium in cancer patients
116. Types and causes of pain in cancer of the head and neck
117. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
118. Effect of tricyclic compounds on membrane binding of bivalent cations, activities of acetylcholinesterase and some tissue proteases
119. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance
120. Tricyclic blood levels and clinical outcome: A review of the art
121. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker
122. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo
123. Behavior of N-acylated daunorubicins in MDR1 gene transfected and parental cells
124. Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses